Editing
Metastatic Hormone-Sensitive Prostate Cancer
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Answers == # Describe the CHAARTED trial. What was the CHAARTED definition of high-volume metastasis? #* Population: 790 men with metastatic castration-sensitive disease #** Stratified by high-volume (visercal metastasis or β₯4 bone lesions with β₯ 1 beyond the vertebral bodies and pelvis) #* Randomized to ADT vs. ADT + docetaxel #* Primary outcome: OS #* Results: #** Median follow-up: 29 months #** Patients receiving chemo had improved OS by 14 months, with benefit only seen in high-volume in stratified analysis # What are the treatment options and which trails support them for: metastatic vs. non-metastatic castrate-sensitive vs. castrate-naiive prostate cancer?
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information